SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough blood cancers: experimental drug targets Treatment-Resistant leukemia
Disease control Recruiting nowThis study is testing an experimental oral drug called NX-5948 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to standard treatments. The drug works differently than previous medications by completely…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for Tough-to-Treat blood cancer patients
Disease control Recruiting nowThis study is testing whether the drug venetoclax can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults whose cancer has come back or stopped responding to other treatments. It is specifically for people who have already tried certain o…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug duo aims to wipe out cancer cells in returning blood cancers
Disease control Recruiting nowThis study is testing whether combining two targeted drugs, zanubrutinib and venetoclax, can effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned after prior therapy. The goal is to see if this combination can achi…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New Triple-Drug attack on blood cancer seeks deep remission
Disease control Recruiting nowThis study is testing a new three-drug combination for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see how many participants achieve a state where no cancer cells can be detected by a very sensitive …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
Cancer study tracks Patients' daily lives for two years
Knowledge-focused Recruiting nowThis study aims to understand how quality of life, fatigue, and symptoms change over two years for adults being treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers will follow 100 participants receiving different treatment types to lear…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC
-
Scientists probe immune System's response to new First-Line cancer pill
Knowledge-focused Recruiting nowThis study aims to understand how the drug pirtobrutinib affects the immune system when used as a first treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers will enroll about 30 adults with untreated CLL or SLL to take the drug daily a…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: EARLY_PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC